Phibro expands autogenous vaccine portfolio, offers solution for antigenic reovirus variations.

April 2, 2020

2 Min Read
vaccine bottles

Reoviruses are constantly changing and evolving, with multiple serotypes that threaten poultry health and performance — until now. Phibro Animal Health Corp.’s latest Tailor-Made autogenous vaccines for poultry reovirus contain farm-specific serotypes, ensuring a close match for the ever-changing field conditions.

“Reovirus strains circulating in the U.S. today are antigenically distinct from classic field strains,” said Phibro U.S. Poultry Business director Tom King. “This volatility means that a vaccine offering good protection today can have limited use in the next flock.”

Autogenous vaccines are uniquely positioned to help poultry producers address the continuous, antigenic changes of reovirus found in the field, the company said. Supported by Phibro’s diagnostics and research and development capabilities, Phibro’s new autogenous vaccine for reovirus solution features the following:

Customized batch-sized flexibility. Phibro can produce batch sizes that enable serotypes to be tailored to each customer’s need. (Batches start at 500 bottles of 1,000 doses.)

Combinable with other autogenous poultry antigens.

Formulated with MVP adjuvants. Phibro’s autogenous vaccines are formulated with proprietary adjuvants, matched to the antigen, host and immune response needed.

Compatible with user-friendly VAC Tracker. The app enables step-by-step, password-protected visibility into the autogenous vaccine manufacturing process, tracking from the arrival of the samples at the laboratory up to shipment of the finished goods.

“Phibro is committed to developing poultry health innovations to address industry needs,” King said. “This reovirus solution will help producers safeguard their flocks from a major threat today, and we’re already developing additional poultry autogenous vaccines to help keep them profitable in the future.”

Phibro’s poultry reovirus autogenous vaccine is for the vaccination of healthy breeder pullets, with a recommended dose of 0.5 mL per pullet by intramuscular or subcutaneous injection.

Contact a Phibro representative to coordinate sample collection to customize and manufacture of autogenous vaccines.

*Potency and efficacy have not been established for autogenous biologics.

Phibro is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for livestock.

Subscribe to Our Newsletters
Feedstuffs is the news source for animal agriculture

You May Also Like